Charles M. Rudin, MD, PhD, on SCLC: Findings on Rovalpituzumab Tesirine
2016 ASCO Annual MeetingCharles M. Rudin, MD, PhD, of Memorial Sloan Kettering Cancer Center, reports on the encouraging anti-tumor activity of this antibody drug conjugate against one of the most deadly malignancies: recurrent or refractory small cell lung cancer (Abstract LBA8505).
Related Videos
Lee S. Schwartzberg, MD, on Progress of the Institute for Clinical Immuno-Oncology
Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.
Eric Roeland, MD, and Jennifer S. Temel, MD, on Integrative Palliative and Oncology Care
Eric Roeland, MD, of the University of California, San Diego, and Jennifer S. Temel, MD, of Massachusetts General Hospital, discuss findings that showed the benefits ...
Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial
Antonio Palumbo, MD, of the University of Torino, discusses this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with rel...
Maria Clemence Schwaederle, PharmD, on Precision Medicine: Its Impact in Refractory Malignancies
Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized s...
Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial
Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplasti...
